Previous 10 | Next 10 |
Axsome Therapeutics (NASDAQ: AXSM ) +44% as Avadel Pharmaceuticals gains 34% on positive data on lead drug. More news on: Axsome Therapeutics, Inc., Avadel Pharmaceuticals plc, Yield10 Bioscience, Inc., Stocks on the move, , Read more ...
100% of animals seroconverted by day 19 at a low dose (2 µg) LUNAR-COV19 remains on track to initiate human clinical trials this Summer SAN DIEGO, April 27, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq...
Developing a vaccine against Covid19 is of obvious global importance. Vaccines stimulate immune systems to produce antibodies, similar to the subject being exposed to the disease. Production of antibodies and stimulation of immune systems help the human body to develop immunity against disease. ...
Market Pulse The COVID-19 pandemic has thrust biopharma to the forefront in the search for a solution. And biotechs will remain at the investing forefront as the quest for anti-viral treatments and vaccines continues to be the race for the holy grail that can restore economic activity around...
SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines,...
Arcturus Therapeutics (NASDAQ: ARCT ) has priced its public offering of ~4.1M common shares at $17.00 per share. Underwriters' over-allotment is an additional ~618K shares. More news on: Arcturus Therapeutics Holdings Inc., Healthcare stocks news, , Stocks on the move, Read more ... ...
SAN DIEGO, April 16, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines,...
Gainers: RCUS +49.2% . LTRPB +13.1% . CGEN +15.9% . AM +15.3% . BBBY +12.1% . More news on: Arcus Biosciences, Inc., Liberty TripAdvisor Holdings, Inc., Compugen Ltd., Stocks on the move, , Read more ...
SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announce...
Clinical Plan Includes Healthy Volunteers in New Zealand and OTC-Deficient Patients Across Several Sites in United States Investor Conference Call at 4:00 pm ET Today SAN DIEGO, April 13, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARC...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...